PRODUCT DETAILS VIEW ALL PRODUCTS

Carvipress Tablets (Carvedilol)

  • Each tablet contains Carvedilol 3.125mg/6.25mg /12.5mg.
  • In treatment of congestive heart failure (CHF), essential hypertension,to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure).
  • Carvedilolis a racemic mixture in which nonselective β-adrenoceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R (+) and S (-) enantiomers at equal potency. It does not have any intrinsic sympathomimetic activity.
  • Heart failure: To be started at 3.125mg twice daily and increase to 6.25, 12.5, and then 25 mg twice daily over intervals of at least 2 weeks. Maintain lower doses if higher doses are not tolerated. Left ventricular dysfunction following myocardial infarction: Start at 6.25 mg twice daily and increase to 12.5 mg then 25 mg twice daily after intervals of 3 to 10 days. A lower starting dose or slower titration may be used. Hypertension: Start at 6.25 mg twice daily and increase if needed for blood pressure control to 12.5 mg then 25 mg twice daily over intervals of 1 to 2 weeks.
  • Carvedilolis contraindicated in Bronchial asthma or related bronchospastic conditions, Second-or third-degree AV block, Sick sinus syndrome, Severe bradycardia, Cardiogenic shock or decompensated heart failure requiring the use of IV inotropic therapy, Severe hepatic impairment and Hypersensitivity
  • Acute exacerbation of coronary artery disease can occur upon cessation of therapy sonot to discontinue abruptly. If bradycardia, hypotension, worsening heart failure/fluid retention occurs reduce the dose as needed. Avoid β-blocker, if deemed necessary, use with caution and at lowest effective dose. In diabetes monitor glucose as β-blockers may mask symptoms of hypoglycemia or worsen hyperglycemia.
  • Pregnancy category C.There are no adequate and well-controlled studies in pregnant women,it is not known whether this drug is excreted in human milk. Safety and effectiveness of Carvedilol inpediatric patients has not been established.
  • CYP P450 2D6 enzyme inhibitors may increase R- enantiomers of carvedilol and rifampin may decrease carvedilol levels. Close monitoring is recommended at the time of administration with Hypotensive agents, Cyclosporine or digoxin. Concomitant use with digitalis glycosides and β-blockerscan increase therisk of bradycardia. Amiodarone may increase carvedilol levels resulting in further slowing of the heart rate or cardiac conduction.Insulin and oral hypoglycemic action may be enhanced. Verapamil- or diltiazem-type calcium channel blockers may affect ECG and/or blood pressure.
  • The most common adverse events are dizziness, fatigue, hypotension, diarrhea, hyperglycemia, asthenia, bradycardia and weight gain.
  • Anti-Hypertensives